SHANK3, the synapse, and autism

New England Journal of Medicine

Volumn 365, Issue 2, 2011, Pages 173-175

  Herbert, Martha R ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR; SCAFFOLD PROTEIN; SH3 AND MULTIPLE ANKYRIN REPEAT DOMAIN 3; UNCLASSIFIED DRUG;

ARTICLE; AUTISM; BRAIN SIZE; CAUDATE NUCLEUS; CHROMOSOME DELETION 22Q11; CORPUS STRIATUM; DENDRITE; GENE; HUMAN; NONHUMAN; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; REMISSION; SHANK3 GENE; SYNAPSE;

EID: 79960231902     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1104261     Document Type: Article

References (5)

1. Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 2011;1380:42-77.
2. Gauthier J, Champagne N, Lafrenière RG, et al. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci U S A 2010;107:7863-8.
3. Hamdan FF, Gauthier J, Araki Y, et al. Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 2011;88:306-16.
4. Peça J, Feliciano C, Ting JT, et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011;472:437-42.
5. Huett A, Leong JM, Podolsky DK, Xavier RJ. The cytoskeletal scaffold Shank3 is recruited to pathogen-induced actin rearrangements. Exp Cell Res 2009;315:2001-11.